Loading
Let validated AI make the first read on routine, high-volume samples like cervical smears and standard breast biopsy stains, so scarce pathologists spend their time on the difficult cases.
Pathology AI is now good enough for narrow, high-volume tasks: cervical cytology screening, prostate biopsy detection, HER2 and ER scoring on breast biopsies. In systems with a fraction of the needed pathologists, an AI-first workflow with pathologist sign-off only on flagged or discordant cases could multiply capacity. The unsolved problems are local validation on different scanners and populations, regulatory acceptance in each jurisdiction, and liability.
Shares PathAI, Paige AI, AI quantification of HER2-low and HER2-ultralow, AI that is built but not validated or deployed.
Shares PathAI, Paige AI, AI quantification of HER2-low and HER2-ultralow, Pathology & radiology foundation models.
Shares PathAI, Paige AI, Pathology & radiology foundation models, AI that is built but not validated or deployed.
Shares PathAI, Owkin, Paige AI, Pathology & radiology foundation models.
Shares Paige AI, Pathology & radiology foundation models, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, Digital pathology & AI.
Shares Owkin, Pathology & radiology foundation models, AI that is built but not validated or deployed, Digital pathology & AI.
Shares Pathology & radiology foundation models, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI that is built but not validated or deployed, Digital pathology & AI.
Shares Lunit, Paige AI, Pathology & radiology foundation models, AI that is built but not validated or deployed.